select a format

Single User License
USD 2000 INR 128180
Site License
USD 4000 INR 256360
Corporate User License
USD 6000 INR 384540

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Female Sexual Dysfunction-Pipeline Review, H1 2016

Female Sexual Dysfunction-Pipeline Review, H1 2016


  • Products Id :- GMDHC8200IDB
  • |
  • Pages: 81
  • |
  • June 2016
  • |
  • |
  Request for Sample Report

Executive Summary

Female Sexual Dysfunction-Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Female Sexual Dysfunction-Pipeline Review, H1 2016', provides an overview of the Female Sexual Dysfunction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction

The report reviews pipeline therapeutics for Female Sexual Dysfunction by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Female Sexual Dysfunction therapeutics and enlists all their major and minor projects

The report assesses Female Sexual Dysfunction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Female Sexual Dysfunction

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Female Sexual Dysfunction pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Female Sexual Dysfunction Overview 8

Therapeutics Development 9

Pipeline Products for Female Sexual Dysfunction-Overview 9

Pipeline Products for Female Sexual Dysfunction-Comparative Analysis 10

Female Sexual Dysfunction-Therapeutics under Development by Companies 11

Female Sexual Dysfunction-Therapeutics under Investigation by Universities/Institutes 12

Female Sexual Dysfunction-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Female Sexual Dysfunction-Products under Development by Companies 16

Female Sexual Dysfunction-Products under Investigation by Universities/Institutes 17

Female Sexual Dysfunction-Companies Involved in Therapeutics Development 18

Apricus Biosciences, Inc. 18

Emotional Brain BV 19

EndoCeutics, Inc. 20

M et P Pharma AG 21

Palatin Technologies, Inc. 22

Re-Pharm Limited 23

TherapeuticsMD, Inc. 24

Valeant Pharmaceuticals International, Inc. 25

Female Sexual Dysfunction-Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Target 28

Assessment by Mechanism of Action 30

Assessment by Route of Administration 32

Assessment by Molecule Type 34

Drug Profiles 36

(sildenafil citrate + testosterone)-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

alprostadil-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

bremelanotide-Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

prasterone-Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

S1B-3006-Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

S1B-307-Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

SIP-104-Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Small Molecule for Sexual Dysfunction-Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

Small Molecules to Agonize Dopamine for Sexual Dysfunction-Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

SPT-201-Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Female Sexual Dysfunction and Erectile Dysfunction-Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

TBS-2-Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

TX-004HR-Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Female Sexual Dysfunction-Dormant Projects 67

Female Sexual Dysfunction-Discontinued Products 70

Female Sexual Dysfunction-Product Development Milestones 71

Featured News & Press Releases 71

May 14, 2016: TherapeuticsMD Presents Poster at ACOG 2016 with Additional Secondary Endpoint Data from Phase 3 Rejoice Trial 71

Mar 02, 2016: TherapeuticsMD to Present Data from Phase 3 Rejoice Trial at Upcoming Investor & Medical Conferences 71

Feb 26, 2016: Palatin Technologies Presents Bremelanotide Alcohol Interaction Study at International Society for the Study of Womens Sexual Health Annual Meeting 72

Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women's Sexual Health Annual Meeting 72

Feb 08, 2016: Palatin Technologies Strengthens Intellectual Property Surrounding Use of Bremelanotide for Female Sexual Dysfunction 73

Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 73

Dec 10, 2015: Palatin Technologies Achieves Target Patient Enrollment in Pivotal Phase 3 Studies for Bremelanotide for Female Sexual Dysfunction 74

Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR 75

Nov 02, 2015: Nicolas Sitchon, CEO of S1 Biopharma, to Present at BIO-Europe 2015 Conference 76

Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting 76

Aug 20, 2015: S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder 76

Aug 19, 2015: Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction 77

Aug 18, 2015: Palatin Technologies Supports FDA's Approval of the First-Ever Treatment for Female Sexual Dysfunction 78

Jun 11, 2015: Trimel Confirms Next FDA Meeting on TEFINA 79

Jun 09, 2015: TherapeuticsMD Completes Enrollment in The Rejoice Trial, a Phase 3 Clinical Trial of TX-004HR 79

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Figures

Number of Products under Development for Female Sexual Dysfunction, H1 2016 9

Number of Products under Development for Female Sexual Dysfunction-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Products, H1 2016 15

Assessment by Monotherapy Products, H1 2016 26

Number of Products by Top 10 Targets, H1 2016 28

Number of Products by Stage and Top 10 Targets, H1 2016 28

Number of Products by Top 10 Mechanism of Actions, H1 2016 30

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 30

Number of Products by Routes of Administration, H1 2016 32

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 32

Number of Products by Molecule Types, H1 2016 34

Number of Products by Stage and Molecule Types, H1 2016 34

List of Tables

Number of Products under Development for Female Sexual Dysfunction, H1 2016 9

Number of Products under Development for Female Sexual Dysfunction-Comparative Analysis, H1 2016 10

Number of Products under Development by Companies, H1 2016 11

Number of Products under Investigation by Universities/Institutes, H1 2016 12

Comparative Analysis by Late Stage Development, H1 2016 13

Comparative Analysis by Clinical Stage Development, H1 2016 14

Comparative Analysis by Early Stage Development, H1 2016 15

Products under Development by Companies, H1 2016 16

Products under Investigation by Universities/Institutes, H1 2016 17

Female Sexual Dysfunction-Pipeline by Apricus Biosciences, Inc., H1 2016 18

Female Sexual Dysfunction-Pipeline by Emotional Brain BV, H1 2016 19

Female Sexual Dysfunction-Pipeline by EndoCeutics, Inc., H1 2016 20

Female Sexual Dysfunction-Pipeline by M et P Pharma AG, H1 2016 21

Female Sexual Dysfunction-Pipeline by Palatin Technologies, Inc., H1 2016 22

Female Sexual Dysfunction-Pipeline by Re-Pharm Limited, H1 2016 23

Female Sexual Dysfunction-Pipeline by TherapeuticsMD, Inc., H1 2016 24

Female Sexual Dysfunction-Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 25

Assessment by Monotherapy Products, H1 2016 26

Assessment by Combination Products, H1 2016 27

Number of Products by Stage and Target, H1 2016 29

Number of Products by Stage and Mechanism of Action, H1 2016 31

Number of Products by Stage and Route of Administration, H1 2016 33

Number of Products by Stage and Molecule Type, H1 2016 35

Female Sexual Dysfunction-Dormant Projects, H1 2016 67

Female Sexual Dysfunction-Dormant Projects (Contd..1), H1 2016 68

Female Sexual Dysfunction-Dormant Projects (Contd..2), H1 2016 69

Female Sexual Dysfunction-Discontinued Products, H1 2016 70

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Apricus Biosciences, Inc.

Emotional Brain BV

EndoCeutics, Inc.

M et P Pharma AG

Palatin Technologies, Inc.

Re-Pharm Limited

TherapeuticsMD, Inc.

Valeant Pharmaceuticals International, Inc.

Female Sexual Dysfunction Therapeutic Products under Development, Key Players in Female Sexual Dysfunction Therapeutics, Female Sexual Dysfunction Pipeline Overview, Female Sexual Dysfunction Pipeline, Female Sexual Dysfunction Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com